A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report
Value in Health · 2023
DOI: 10.1016/j.jval.2023.04.007 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Value in Health, 2023. Verfasst von Evelien Moorkens und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 87 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: This study aims to provide an overview of the gaps and challenges in the value assessment of biosimilars and to identify potential approaches to address them. METHODS: A multidisciplinary, international team of biosimilar experts identified gaps and challenges. A systematic review was conducted of the peer-reviewed literature in PubMed, EMBASE, Web of Science Core Collection, EBSCOhost Business Source Complete; and of the gray literature. Preliminary results were presented at ISPOR conferences and this article benefited from 2 review rounds among ISPOR Biosimilar Special Interest Group members. RESULTS: Given that a biosimilar is highly similar to its reference biologic, health technology assessment agencies should accept the comparability exercise approved by regulatory authorities and, thus, conduct a price comparison when biosimilar reimbursement is requested for the same indication as the reference biologic. If the reference biologic is not reimbursed or is not the standard of care, a full economic evaluation of the biosimilar versus a relevant comparator needs to be conducted. To date, little consideration has been given to specific challenges, such as how biosimilar value assessment can account for the nocebo effect, potential differences between biologic-naive and biologic-experienced patients, the availability of intravenous and subcutaneous administration forms or different administration devices for the same active compound, value-added services, and the contribution of biosimilars for generating health gain at the population level. CONCLUSIONS: There is a need to gather further insights in the methodology of value assessment for biosimilars, and health technology assessment agencies need to develop more elaborate guidance on biosimilar value assessment in specific circumstances.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
- National Institute for Health and Care Excellence (NICE), London, England, UK; Department of Clinical Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
- Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary; Syreon Research Institute, Budapest, Hungary.
- Department of Pharmacy Management, Manipal College of Pharmaceutical Sciences, Manipal, India.
- Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.
- School of Population Health & Environmental Sciences, Faculty of Life Sciences & Medicine, King's College London, London, England, UK; Biomedical Research Centre, National Institute for Health Research (NIHR), Guy's and…
Zitieren
APA
Moorkens, E., Lacosta, T. B., Dawoud, D., Inotai, A., Janodia, M., Tan, C. J., Lim, K. K., Khatri, N., Pereira, C. L., & Simoens, S. (2023). A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in Health. https://doi.org/10.1016/j.jval.2023.04.007
Vancouver
Moorkens E, Lacosta TB, Dawoud D, Inotai A, Janodia M, Tan CJ, et al. A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report. Value in Health. 2023. doi:10.1016/j.jval.2023.04.007
BibTeX
@article{Moorkens2023,
author = {Moorkens, Evelien and Lacosta, Teresa Barcina and Dawoud, Dalia and Inotai, András and Janodia, Manthan and Tan, Chia Jie and Lim, Ka Keat and Khatri, Nishtha and Pereira, Catarina Lopes and Simoens, Steven},
title = {A Systematic Literature Review of Gaps and Challenges in Value Assessment of Biosimilars: An ISPOR Special Interest Group Report},
journal = {Value in Health},
year = {2023},
doi = {10.1016/j.jval.2023.04.007}
}
EUVIMED